ERBB2 and breast cancer: As expected, we confirmed that loss of USP22 impairs the expression of several chemotherapy resistance-associated genes (Fig. S3F) and sensitizes TNBC and HER2+-BC cells to increasing doses of cisplatin and lapatinib, respectively (Fig. 6A), pointing to an important role of USP22 in promoting drug-tolerance of BC cells.